Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Endoluten5 residuesAEDLVEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: A-8, Pineal Bioregulator A-8
A 6 to 8 year follow-up of 266 elderly subjects found that combined pineal and thymic peptide treatment reduced mortality up to 4.1-fold compared to controls (Khavinson and Morozov)[1]. Endoluten is an oral bioregulator extracted from bovine pineal glands, containing the same AEDG and EDR peptide sequences found in synthetic Epithalon and Pinealon. All primary human evidence comes from a single Russian research institute with no Western replications. Adults over 40 with declining melatonin production and disrupted circadian rhythm are the primary users, typically running 10-day oral courses repeated every 3 to 6 months per the Khavinson protocol.
A 4.1-fold reduction in mortality over 6 to 8 years. That's what Khavinson and Morozov reported in 266 elderly subjects taking combined pineal and thymic peptide preparations [1]. The pineal component was Endoluten, designated A-8, an acid-extracted polypeptide complex from the pineal glands of calves under 12 months old. Mass spectrometry confirmed AEDG tetrapeptide among Endoluten's bioactive components [2]. AEDG is the same sequence found in synthetic Epithalon, studied for telomerase activation. The preparation also contains EDR (Glu-Asp-Arg), a tripeptide independently characterized for MAPK/ERK neuroprotection [3]. Other peptide fractions in the extract remain uncharacterized. The proposed mechanism follows Khavinson's bioregulator model. Short-chain peptides bind gene promoter regions in pinealocytes. This restores melatonin biosynthesis without requiring continuous supplementation. A separate study confirmed normalization of nighttime melatonin rhythm in elderly subjects and aged monkeys [4]. In practice, users take 2 capsules (20 mg) daily for 10 consecutive days, repeating every 3 to 6 months. Sleep quality improvement is the most consistently reported benefit across Longecity and ProjectBioHacked forums. Effects are described as subtle, cumulative across courses, and most noticeable in older adults with already-declining melatonin output. The honest assessment: all primary human data originates from the St. Petersburg Institute of Bioregulation and Gerontology. Published work used non-blinded, non-randomized cohort designs. No Western lab has independently replicated the mortality findings. Oral bioavailability of the specific peptide mixture hasn't been formally characterized. The science behind the individual peptides (AEDG and EDR) is stronger than the evidence for Endoluten's full extract.
Endoluten's activity traces to its constituent short-chain peptides interacting directly with pinealocyte DNA. The AEDG tetrapeptide component activates telomerase and promotes normalized melatonin synthesis in pineal gland tissue. AEDG has been identified within the extract by mass spectrometry [2]. The EDR tripeptide component operates through a different pathway. EDR regulates the MAPK/ERK signaling cascade, specifically inhibiting ERK1/2 activation under oxidative stress conditions [3]. EDR also upregulates superoxide dismutase 2 (SOD2) and glutathione peroxidase 1 (GPx1) expression in brain tissue. At the cellular level, this reduces caspase-3-mediated apoptosis in neural tissue and preserves dendritic spine morphology. The Khavinson bioregulator model proposes these peptides bind specific DNA promoter sequences in target cells. A 10-day course is theorized to trigger lasting epigenetic changes in gene expression. This would explain why benefits persist for months after the capsules are finished. Cycling is built into the foundational mechanism hypothesis itself, not derived from receptor desensitization or hormonal axis suppression concerns. Khavinson's 2007 study [4] confirmed that pineal peptide preparations restored nocturnal melatonin secretion patterns in both elderly human subjects and aged monkeys. The circadian rhythm normalization tracked with changes in pinealocyte function, not exogenous hormone supplementation.
Human observational data from the Khavinson Institute shows pineal peptide preparations restore melatonin secretion and reduce all-cause mortality in elderly cohorts. The landmark 2003 study (n=266, 6–8 year follow-up)[1] found combined pineal + thymic peptide treatment reduced mortality up to 4.1-fold vs. controls. Constituent peptides AEDG (Epithalon sequence) and EDR (Pinealon sequence) have independently characterized mechanisms in peer-reviewed literature: telomerase activation and MAPK/ERK neuroprotection respectively. However, no Western RCTs exist. All primary human evidence originates from one research group using non-blinded, non-randomized cohort designs published largely in Russian-language or institute-affiliated journals.
Khavinson & Morozov (2003): "Peptides of pineal gland and thymus prolong human life." Neuroendocrinology Letters. 266 elderly subjects, 6–8 year follow-up; combined pineal + thymic peptide protocol reduced mortality 4.1-fold vs. controls. PMID 14523363.
No randomized, blinded, or placebo-controlled trials. All human evidence from one institute (St. Petersburg Institute of Bioregulation and Gerontology). Published primarily in Russian-language or non-indexed journals. Oral bioavailability of short-chain peptides uncertain: gastric degradation not formally characterized for Endoluten's specific peptide mixture. Prion risk from bovine pineal tissue cannot be formally excluded despite manufacturer's <5 kDa molecular-weight filtering claim (unverified independently). No Western independent replications as of 2026.
Very niche compound discussed primarily in dedicated bioregulator communities (Longecity, ProjectBioHacked) rather than general peptide forums. Sleep quality improvement is the most consistently reported benefit, typically noticed within days 4–7 of a 10-day course. Effects described as subtle and cumulative over multiple courses. Community members generally accept the theoretical prion risk as negligible given decades of use without documented incidents. Many users consider switching to synthetic Epithalon (AEDG) or Pinealon (EDR) due to lower cost and better-defined pharmacology.
Both scientific literature and community experience converge on melatonin normalization and sleep quality improvement as the primary effect. Science frames this as epigenetic restoration of pinealocyte function; community reports sleep improvement: mechanistically consistent outcomes. The gap is in magnitude of claim: Khavinson's data asserts mortality reduction; the community reports more modest, near-term sleep/circadian benefits.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 20mg | Daily |
| Moderate | 20mg | Daily |
| Aggressive | 20mg | 2x Daily |
Endoluten comes as oral capsules, so there's no reconstitution math to worry about. Each capsule contains approximately 10 mg of the purified peptide complex. The standard Khavinson protocol is 2 capsules per day for 10 days. That's 20 capsules per course, roughly $70 per course from legitimate distributors. Sourcing is the thing most beginners miss. Legitimate Endoluten carries the Khavinson Institute A-8 designation and is manufactured by Garmonia LLC in Russia. Cosmic Nootropic and Antiaging Systems (UK) are the most commonly cited distributors in community discussions. Counterfeits exist; check for the A-8 label and verify lot numbers when possible. Take capsules whole, not opened or crushed. Morning dosing is the Khavinson standard, 10 to 15 minutes before breakfast. If drowsiness hits during the day, evening dosing works fine too. The effects build up over multiple courses. Don't judge after one 10-day cycle. Most users run 2 to 3 courses per year and report cumulative improvement.
Standard Khavinson bioregulator protocol: 1-2 capsules daily for 10 days, repeated every 3-6 months. For more pronounced conditions, courses of 15-60 days have been used under medical supervision.
The Khavinson bioregulator model proposes that short-chain peptides bind specific DNA promoter sequences in target tissue (pinealocytes) and restore normal gene expression. Under this model, a 10-day course is theoretically sufficient to trigger lasting epigenetic changes: continuous supplementation is neither part of the validated protocol nor theorized to be necessary. Cycling is built into the foundational mechanism hypothesis, not derived from receptor desensitization, antibody formation, or hormonal axis suppression concerns.
Or use the universal Peptide Calculator for any peptide.
Expected: Improved sleep onset and quality within days 4–7; circadian rhythm normalization; effects may persist for 1–3 months post-course due to lasting epigenetic changes in pinealocyte gene expression
Monitor: No mandatory lab monitoring for standard preventive protocol. Sleep diary or wearable sleep tracker recommended to objectively capture the primary endpoint.
Confirm your capsules display the Khavinson Institute A-8 designation on the packaging. Each capsule contains approximately 10 mg of the peptide complex.
Take 2 capsules by mouth with water, 10 to 15 minutes before breakfast. Swallow whole. Do not open or crush capsules.
No titration is needed; start at 2 capsules (20 mg) from day 1.
The protocol calls for a 3 to 6 month break before repeating. Most users do 2 to 3 courses per year.
If morning dosing causes daytime drowsiness, switch to evening dosing (before dinner). Both timings are community-accepted.
Store capsules in original packaging at room temperature (2 to 25 degrees Celsius), protected from moisture and light. Shelf life is up to 3 years when stored properly.
Track your sleep quality with a diary or wearable tracker throughout the course and for 4 to 8 weeks afterward. This is the most practical way to measure whether Endoluten is working for you.
Note: No injection, no bacteriostatic water, no insulin syringes. This is one of the simplest peptide-class products to administer.
Thymus bioregulator; provides immune system support. Classic Khavinson combination: the landmark PMID 14523363 mortality study used combined pineal + thymic peptide treatment. Complementary organ-system targeting without mechanistic overlap.
Brain bioregulator (A-5 peptide complex). Standard Khavinson multi-organ protocol includes combined brain + pineal gland support. No mechanistic overlap; complementary targets.
Delta sleep-inducing peptide; acts on NREM sleep promotion via a distinct hypothalamic mechanism. Complementary to Endoluten's melatonin restoration approach: different pathway, potential additive sleep quality benefit.
Endoluten already contains AEDG (the Epithalon sequence). Stacking synthetic Epithalon on top of Endoluten creates redundant, potentially excessive AEDG exposure with no documented additional benefit. Choose one or the other; do not combine.
Endoluten already contains EDR (the Pinealon sequence). Stacking synthetic Pinealon on top of Endoluten creates redundant EDR exposure. No benefit; unnecessary additional dose and cost.
Endoluten's mechanism is to restore endogenous pineal melatonin production. Taking exogenous melatonin concurrently may suppress the pineal gland further (negative feedback), directly counteracting what Endoluten aims to achieve. Use one or the other.
Additive CNS sedation. Endoluten increases endogenous melatonin production; combining with prescription sedatives or hypnotics may cause excessive daytime drowsiness or over-sedation at night.
Pricing updated 2026-04-09
The most serious concern with Endoluten is its origin: bovine pineal tissue. Any product derived from bovine central nervous system tissue carries a theoretical prion transmission risk. No documented cases of prion disease from Endoluten or any Khavinson bioregulator have been reported in over 20 years of commercial use. The manufacturer (Garmonia LLC) claims molecular-weight filtering below 5 kDa would exclude prion particles. That filtering claim has not been independently verified by any Western laboratory. Practical risk assessment matters here. Decades of use across Russian-speaking markets have produced zero documented prion incidents. Community users on Longecity generally accept this risk as negligible. But "no documented cases" and "proven safe" are not the same thing; the absence of formal pharmacovigilance monitoring means adverse events could go unreported. Allergic reactions to bovine-derived proteins represent the next category of concern. Individuals with known sensitivity to animal-derived protein preparations should avoid Endoluten entirely. Signs to watch for include rash, urticaria, and GI distress beyond normal adjustment. Stop immediately if any allergic symptoms appear. Common side effects reported in community discussions and product literature include mild gastrointestinal discomfort (nausea, bloating) during the first 1 to 2 days of a course. Taking capsules with a light snack rather than on a completely empty stomach typically resolves this. Timing flexibility of plus or minus 30 minutes around meals is acceptable within the Khavinson protocol. Transient daytime drowsiness is reported by some users, likely connected to increased endogenous melatonin production. If morning dosing causes drowsiness, shifting to evening administration is community-accepted. Headache appears in product literature but isn't frequently mentioned in community threads. The total number of humans formally studied with Endoluten-containing preparations across all Khavinson Institute publications is approximately 266 in the landmark mortality study, with smaller numbers in melatonin normalization studies. No large-scale safety monitoring programs exist outside Russian institutional research. Endoluten should not be taken during pregnancy or breastfeeding; no safety data exists for these populations. Children and adolescents under 18 should not use it. Anyone with active autoimmune conditions should exercise caution, as pineal peptides may modulate immune function through pathways that are not fully characterized. Combining Endoluten with exogenous melatonin supplements is counterproductive. The entire mechanism aims to restore your pineal gland's own melatonin output. Adding exogenous melatonin may suppress pineal function through negative feedback, directly opposing what Endoluten is trying to accomplish. Combining with sedative medications (benzodiazepines, Z-drugs) risks additive CNS sedation. If you experience anything beyond mild GI adjustment or transient drowsiness, stop the course and consult a physician. No formal drug interaction studies have been conducted for Endoluten.
Verify Endoluten dosing and safety with a second opinion
Bovine pineal tissue-derived polypeptide extract. Primary manufacturer (Garmonia LLC, Russia) operates under no Western regulatory equivalent to FDA GMP standards. No third-party independent purity or potency testing is publicly available. Counterfeit Khavinson bioregulators exist in the market. Theoretical prion risk from bovine CNS tissue cannot be formally excluded despite the manufacturer's <5 kDa molecular-weight filtering claim (this claim has not been independently verified). No regulatory approval in EU, US, UK, or any other major Western market.
| Test | When | Target |
|---|---|---|
| Serum melatonin (nocturnal) | Before first course and 2–4 weeks after completing first course (nocturnal draw, ideally 2–3am) | Nocturnal peak: 100–300 pg/mL; age-dependent norms apply (elderly patients typically have lower baselines) |
| Sleep diary or wearable sleep tracking | Throughout course and 4–8 weeks post-course | — |
Most direct biomarker of Endoluten's proposed mechanism: normalization of endogenous melatonin production in pineal gland
Most practical surrogate for melatonin normalization and the primary community-reported endpoint; useful for tracking course-to-course response
Minimal noticeable effects. Some users report subtle improvements in sleep onset.
Gradual improvement in sleep quality and duration as melatonin synthesis begins to normalize.
Peak effects of the initial course. More consistent sleep-wake patterns and improved subjective energy levels in responsive individuals.
Benefits typically persist for several months after completing a 10-day course due to lasting epigenetic changes in pinealocyte gene expression.
Days 1 to 3: Don't expect to feel anything yet. The peptide complex is beginning to interact with pinealocyte gene promoter regions, but no measurable changes in melatonin output happen this early. Some users notice mild GI adjustment on days 1 to 2, especially if taken on an empty stomach. That's normal. Days 4 to 7: This is the window where most community users first notice something. Faster sleep onset and fewer nighttime awakenings are the two most commonly mentioned changes. The science side lines up too; if epigenetic changes in pinealocyte gene expression are occurring, melatonin synthesis normalization would begin around this point. Some users report transient daytime drowsiness. Days 8 to 10: Peak effects of the 10-day course. Sleep-wake patterns become more consistent in responsive individuals. Subjective energy levels improve for some. Results are highly variable, the community is honest about this. Some users finish the course without noticing much change at all. Weeks 2 to 12 (post-course): This is the interesting part. Benefits typically persist for 1 to 3 months after completing a 10-day course. The Khavinson model attributes this to lasting epigenetic changes in pinealocyte gene expression that don't require continuous supplementation. Some users notice a gradual return of previous sleep patterns around month 3, which triggers the next course. Months 3 to 6: Time to repeat. The Khavinson protocol specifies repeating every 3 to 6 months. Most users settle on 3 to 4 month intervals if benefits have clearly faded. Elderly users pursuing broad geroprotection rather than sleep-specific effects sometimes run courses annually or biannually.
Peptide complex begins interacting with pinealocyte gene promoter regions. No measurable changes in melatonin output expected at this stage.
Most users report nothing noticeable. Occasional mild GI adjustment on days 1–2 in sensitive individuals.
If epigenetic changes are occurring in pinealocyte gene expression, melatonin synthesis normalization may begin within this window.
Most commonly reported window for first noticeable sleep improvement. Users describe faster sleep onset and fewer nighttime awakenings.
Peak epigenetic effect from the 10-day course per Khavinson model. If melatonin normalization is occurring, it should be most apparent at this stage.
More consistent sleep-wake patterns and improved subjective energy in responsive individuals. Highly variable: some users notice little change.
The theoretical basis for the 10-day protocol design: lasting epigenetic changes in pinealocyte gene expression should persist for months, not requiring continuous supplementation.
Benefits reported to persist 1–3 months after a 10-day course. Some users notice gradual return of previous sleep patterns near month 3, prompting repeat dosing.
Khavinson protocol specifies repeat every 3–6 months. No comparative data on whether shorter intervals are more effective.
Most users repeat at 3–4 months if benefits have clearly faded. Annual or biannual dosing in elderly users seeking broad geroprotection rather than sleep-specific effects.
Source: Estimated from polypeptide fraction kinetics; individual component PK not characterized (Khavinson & Morozov, 2003)
Loading the interactive decay curve.
Endoluten has no FDA approval and no regulatory approval in the EU, UK, or any other major Western market. It is classified as research-only in the United States. In Russia, Khavinson bioregulators are registered as dietary supplements (biologically active additives) rather than pharmaceuticals. Importing Endoluten for personal use into the US, UK, and most EU countries sits in a gray area. Customs seizure is possible but uncommon based on community reports. The product is not a controlled substance in any jurisdiction. For athletes, no WADA status has been established for Endoluten specifically. The individual constituent peptides (AEDG, EDR) don't appear on the current WADA prohibited list, but athletes subject to drug testing should verify current regulations before use. The primary legitimate manufacturer is Garmonia LLC (Russia), operating under the Khavinson Institute framework. Western GMP-equivalent manufacturing standards have not been confirmed for this producer. This content is for educational and research purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before using any peptide product.
Peptide Schedule Research TeamReviewed Apr 20265 Citations
